Challenges of conducting a trial of uric-acid-lowering therapy in CKD

Badve, Sunil V., Brown, Fiona, Hawley, Carmel M., Johnson, David W., Kanellis, John, Rangan, Gopala K. and Perkovic, Vlado (2011) Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nature Reviews Nephrology, 7 5: 295-300. doi:10.1038/nrneph.2010.186

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
Badve_Sunil_authoraffil_staffdata.pdf Badve_Sunil_authoraffil_staffdata.pdf application/pdf 198.32KB 0
Hawley_Carmel_authoraffil_staffdata.pdf Hawley_Carmel_authoraffil_staffdata.pdf application/pdf 231.36KB 0
Johnson_David_authoraffil_staffdata.pdf Johnson_David_authoraffil_staffdata.pdf application/pdf 222.26KB 0

Author Badve, Sunil V.
Brown, Fiona
Hawley, Carmel M.
Johnson, David W.
Kanellis, John
Rangan, Gopala K.
Perkovic, Vlado
Title Challenges of conducting a trial of uric-acid-lowering therapy in CKD
Journal name Nature Reviews Nephrology   Check publisher's open access policy
ISSN 1759-5061
1759-507X
Publication date 2011-05
Sub-type Article (original research)
DOI 10.1038/nrneph.2010.186
Volume 7
Issue 5
Start page 295
End page 300
Total pages 6
Place of publication London, United Kingdom
Publisher Nature Publishing Group
Collection year 2012
Language eng
Abstract Observational studies have shown that asymptomatic hyperuricemia is associated with increased risks of hypertension, chronic kidney disease (CKD), end-stage renal disease, cardiovascular events, and mortality. Whether these factors represent cause, consequence or incidental associations, however, remains uncertain. Hyperuricemia could be a consequence of impaired kidney function, diuretic therapy or oxidative stress, such that elevated serum urate level represents a marker, rather than a cause, of CKD. On the other hand, small, short-term, single-center studies have shown improvements in blood-pressure control and slowing of CKD progression following serum urate lowering with allopurinol. An adequately powered randomized controlled trial is required to determine whether uric-acid-lowering therapy slows the progression of CKD. This article discusses the rationale for and the feasibility of such a trial. International collaboration is required to plan and conduct a large-scale multicenter trial in order to better inform clinical practice and public health policy about the optimal management of asymptomatic hyperuricemia in patients with CKD. © 2011 Macmillan Publishers Limited. All rights reserved.
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2012 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 17 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 21 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 23 Mar 2011, 14:58:24 EST by Debbie Banks on behalf of School of Medicine